Inhibikase Therapeutics, Inc. (IKT)

NCM – Real Time Price. Currency in USD

1.91

+0.04 (2.14%)

At close: Jun 26, 2026, 4:00 PM EDT

1.92

+0.01 (0.52%)

After-hours: Jun 26, 2026, 5:21 PM EDT

12.05.2026

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2026, and highlighted recent developments.

07.04.2026

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that the first patient has been enrolled in the Company's pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332).

03.04.2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.68 per share, which is equal to the closing price of the Company's common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company's Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants.

26.03.2026

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the year ended December 31, 2025 and highlighted recent developments.

21.11.2025

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional 10,344,827 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Inhibikase from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. All of the securities being sold in the offering are being offered by Inhibikase. The offering is expected to close on November 24, 2025, subject to the satisfaction of customary closing conditions.

20.11.2025

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Inhibikase intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock Inhibikase is offering, at the public offering price, less underwriting discounts and commissions. All of the securities being sold in the proposed offering are being offered by Inhibikase. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

20.11.2025

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in PAH. The Phase 3 study, named IMPROVE-PAH ( I KT-001 for M easuring P ulmonary Vascular R esistance and O utcome V ariables in a Phase 3 E valuation of PAH ), is expected to be initiated in the first quarter of 2026.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

07.04.2026

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

03.04.2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26.03.2026

Inhibikase Therapeutics, Inc. (IKT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Videos

No Data

Press releases

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Videos

No Data

Press releases

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Search stocks

Inhibikase Therapeutics, Inc. (IKT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Videos

No Data

Press releases

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Videos

No Data

Press releases

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity